hotspot -WSS

hotspot

author：fashion 2025-10-01 11:34:28 - browse：89378

Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT — Adobe

In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Disappointing trial forces Pfizer to pivot on obesity medicine plans

hotspot

WSS

Alexander Hamilton and the argument for universal insurance

Cigna, Humana reportedly in talks to merge

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Biden to sign 'historic' executive order on how US military handles sexual assault cases

FDA investigates CAR

As the dark side of IVF slowly comes into focus, even more transparency is needed

focus

hotspot

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

focus

Medicare proposal to cover medical devices draws a mixed reaction

Takeda, Janssen join wearable maker to measure scratching

Medicare details structure of new drug price negotiation program

Diagnostic tests are hitting their mathematical limits

Supreme Court strikes down use of affirmative action

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

UnitedHealth’s Optum accused of antitrust violations in California

Walensky prepares to leave CDC — and Congress — behind

Ending health disparities requires full federal government, panel says

hotspot

Disappointing trial forces Pfizer to pivot on obesity medicine plans

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Alexander Hamilton and the argument for universal insurance

Pediatric cancer treatments threatened by a new FDA policy

U.K. Biobank has 500,000 peoples' genome sequences available

hotspot

focus

hotspot

hotspot